This poster, presented at MDA 2026, highlights real-world safety data for the branded formulation of deflazacort in patients with Duchenne muscular dystrophy (DMD) using reports from the FDA Adverse Event Reporting System (FAERS) database
Muscular Dystrophy Association (MDA) Annual Clinical & Scientific Conference
The Muscular Dystrophy Association (MDA) Annual Clinical & Scientific Conference brings together scientists and clinicians from around the world to present their results, form new collaborations and learn the latest developments in the field.
Please select the resource of interest below:
|
Congress
Topic
Type
Year
Access PTC abstracts, infographics, posters and symposia presented at international meetings in the fields of pediatric neurology, cognitive neuroscience and movement disorders, such as the Muscular Dystrophy Association (MDA) Annual Clinical & Scientific Conference, the Child Neurological Society (CNS) Annual Meeting, the World Muscle Society (WMS) Annual Congress, and International Congress on Neuromuscular Diseases (ICNMD).
Always consult the prescribing information before prescribing any products
MED-US-CORP-2500008 | November 2025
MED-US-DMD-2600002 | September 2026